Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has announced its participation in four major upcoming investor conferences in June 2025:
- William Blair Growth Stock Conference (June 3-5) in Chicago - Including corporate presentation and fireside chat
- Jefferies Global Healthcare Conference (June 3-5) in New York - Featuring corporate presentation with webcast availability
- Goldman Sachs Global Healthcare Conference (June 9-11) in Miami
- Scotiabank Healthcare Canadian Investor Day (June 17) in Toronto
The company will conduct one-on-one meetings at all events, with a live webcast available for the Jefferies presentation through Viking's website.
Viking Therapeutics (VKTX) has reported its Q1 2025 financial results and provided key updates on its clinical pipeline. The company ended the quarter with a strong cash position of $852 million, down from $903 million in December 2024. The quarter saw a net loss of $45.6 million ($0.41 per share), compared to $27.4 million ($0.26 per share) in Q1 2024.
Key developments include:
- Phase 3 trials for subcutaneous VK2735 obesity treatment expected to begin in Q2 2025
- Completion of enrollment in Phase 2 VENTURE-Oral Dosing trial, with data expected in 2H 2025
- New manufacturing agreement with CordenPharma for VK2735 commercialization
- Advancement of novel amylin agonist program with IND filing planned for 2H 2025
R&D expenses increased to $41.4 million from $24.1 million year-over-year, while G&A expenses rose to $14.1 million from $10.0 million.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company specializing in metabolic and endocrine disorder therapies, has scheduled its first quarter 2025 financial results release for April 23, 2025, after market close.
The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss financial results and corporate updates. Participants can join via phone (U.S.: 844-850-0543; International: 412-317-5199) or through the company's website. A replay will be available until April 30, 2025, using access code #8779272.
Viking Therapeutics (NASDAQ: VKTX) has completed enrollment in its Phase 2 VENTURE-Oral Dosing Trial of VK2735, a dual GLP-1 and GIP receptor agonist tablet for obesity treatment. The 13-week study enrolled 280 adults with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with weight-related conditions.
The trial's primary endpoint focuses on body weight change after 13 weeks, with results expected in 2H25. Previous Phase 1 results showed promising outcomes, with weight reductions up to 8.2% after 28 days and up to 8.3% at follow-up. The drug demonstrated favorable safety profile with 99% of adverse events being mild or moderate.
Notably, Viking is also developing a subcutaneous formulation of VK2735, which showed significant results in its Phase 2 VENTURE study with weight reductions up to 14.7%. The company plans to initiate Phase 3 development for the subcutaneous formulation in 1H25.
Viking Therapeutics (VKTX) has entered a multi-year strategic partnership with CordenPharma for the development and manufacturing of its GLP-1 drug candidate VK2735. The partnership encompasses the full supply chain from drug substance to drug product for both subcutaneous and oral peptide formulations.
CordenPharma will provide large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance, along with fill-finish services for the subcutaneous formulation and oral solid dosage manufacturing. The agreement leverages CordenPharma's global network of manufacturing facilities, featuring built-in redundancy through multiple drug substance sites to ensure uninterrupted supply throughout the product lifecycle.
Viking Therapeutics (NASDAQ: VKTX) has secured a major manufacturing agreement with CordenPharma for its VK2735 obesity treatment program. The multi-year contract ensures dedicated production capacity for both subcutaneous and oral formulations to support potential multi-billion-dollar annual product sales.
The agreement includes:
- Annual production capacity for multiple metric tons of VK2735 API
- 100 million autoinjectors and 100 million vial/syringe products annually
- Over 1 billion oral tablets manufacturing capacity per year
Viking will make prepayments totaling $150 million between 2025-2028, which will be credited against future orders. The company maintains all global rights to VK2735 and expects standard pharmaceutical product margins. Currently, VK2735 is in Phase 2 VENTURE-Oral Dosing Trial, with Phase 3 development for the subcutaneous formulation planned for Q2 2025.
Viking Therapeutics (NASDAQ: VKTX) has announced its participation in two major upcoming investor conferences in March 2025. The company will attend the Leerink Partners Global Healthcare Conference 2025 from March 10-12, where management will engage in a fireside chat on March 11 from 9:20 to 9:50 a.m. Eastern, along with one-on-one meetings.
Additionally, Viking management will participate in the Jefferies Biotech on the Beach Summit from March 11-12, 2025, conducting one-on-one meetings. Both events will take place in Miami, FL. A live webcast of the Leerink presentation will be available through Viking's website in the Investors & Media section, with a replay accessible post-conference.
Viking Therapeutics (VKTX) reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical pipeline. The company plans to initiate Phase 3 studies for its obesity treatment VK2735 in Q2 2025, following positive Phase 2 VENTURE study results showing up to 14.7% body weight reduction. A Phase 2 trial for an oral version of VK2735 is currently underway.
Financial highlights include a strong cash position of $903 million at year-end 2024. The company reported a Q4 net loss of $35.4 million ($0.32 per share) and full-year net loss of $110.0 million ($1.01 per share). R&D expenses increased to $101.6 million for 2024, up from $63.8 million in 2023.
Viking Therapeutics (NASDAQ: VKTX) has scheduled its fourth quarter and year-end 2024 financial results release for February 5, 2025, after market close. The clinical-stage biopharmaceutical company, which focuses on developing novel therapies for metabolic and endocrine disorders, will host a conference call at 4:30 p.m. Eastern Time on the same day.
Participants can join the call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 internationally. A replay will be available until February 12, 2025, accessible by dialing (877) 344-7529 (U.S.) or (412) 317-0088 (international) with replay code #6731266. The webcast will be available on Viking's website and archived for 30 days.
Viking Therapeutics (NASDAQ: VKTX) has initiated a Phase 2 VENTURE-Oral Dosing Trial for VK2735, their dual GLP-1 and GIP receptor agonist in tablet form. The 13-week study will evaluate safety, tolerability, pharmacokinetics, and weight loss efficacy in approximately 280 adults who are obese or overweight with comorbidities.
Previous 28-day Phase 1 results showed promising outcomes, with participants experiencing dose-dependent weight reductions up to 8.2%, and persistent effects up to 8.3% four weeks post-treatment. Up to 100% of treated subjects achieved ≥5% weight loss, compared to 0% for placebo. The treatment demonstrated good tolerability, with 99% of adverse events being mild or moderate.
Concurrently, Viking is advancing a subcutaneous formulation of VK2735, which showed significant results in its Phase 2 VENTURE study, with weight reductions up to 14.7%. The company plans to initiate Phase 3 development for the subcutaneous formulation in first half of 2025.